Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

Morphotek and NCI sign agreement to develop antibodies for the treatment of various cancers

Jan. 19, 2004

Dosing commenced in phase II adult AML trial of clofarabine

Jan. 16, 2004

SB-715992 enters broad phase II program for cancer

Jan. 16, 2004

Novel class of farnesyltransferase inhibitors synthesized by Abbott

Jan. 15, 2004

MPI-176716 produces tumor regression in animal models of ovarian cancer

Jan. 15, 2004

BioStratum and Novo Nordisk to develop antibodies to laminin-5 for cancer

Jan. 15, 2004

Eloxatin approved for first-line treatment of advanced colorectal cancer

Jan. 15, 2004

BMS scientists claim Eg5 inhibitors and their use in cancer therapy

Jan. 15, 2004

Pierre Fabre presents protein prenyltransferase inhibitors for cancer and other disorders

Jan. 15, 2004

A new phase II clinical trial to evaluate Davanat with 5-FU in refractory colorectal cancer

Jan. 14, 2004

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 2, 2026.
With improved technologies, biomarkers, failed drugs may come into their own
BioWorld
At BioEurope Spring 2026, pharma representatives and investors shared their thoughts about current and future landscapes of different disease areas, and on how to...
Small-molecule TREM2 agonist advances to treat Alzheimer’s
BioWorld Science
Microglia play a central role in the neuroinflammation associated with Alzheimer’s disease (AD). These cells act as the brain’s immune system and respond to...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 31, 2026
Amlogenyx’s AM-805 reduces amyloid plaques in AD
BioWorld Science
The potent carboxypeptidase enzyme protective protein cathepsin A (PPCA) is known to cleave the C-terminus of amyloid-β42, responsible for aggregation and...